Frequently Asked Questions about Gilead Sciences, Inc. (GILD)

Name: Gilead Sciences, Inc. (GILD) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Gilead Sciences, Inc. (GILD) do?

Accepted Answer

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla pro...

Question 2

Is Gilead Sciences, Inc. (GILD) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of GILD reveals an Altman Z-Score of 4.18 and a Piotroski F-Score of 8/9. These metrics, combined with its 5-year revenue trend ($29.44B most recent), help investors decide if GILD fits their risk profile.

Question 3

What is the current P/E ratio for GILD?

Accepted Answer

As of the latest trading session, Gilead Sciences, Inc. (GILD) has a trailing P/E ratio of 20.60.

Question 4

Who is the CEO of Gilead Sciences, Inc.?

Accepted Answer

The current Chief Executive Officer of Gilead Sciences, Inc. is Daniel O'Day.

Question 5

What was GILD's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Gilead Sciences, Inc. reported annual revenues of $29.44B (2025), $28.75B (2024), $27.12B (2023), $27.28B (2022), $27.30B (2021) respectively.

Question 6

Does GILD pay a dividend?

Accepted Answer

Gilead Sciences, Inc. currently pays a dividend to its shareholders, with a trailing dividend yield of 2.26%.

Question 7

How much debt and cash flow does GILD have?

Accepted Answer

In its latest reporting period, Gilead Sciences, Inc. generated $9.46B in Free Cash Flow against a total debt load of $24.59B.

Question 8

What is the Price-to-Book (P/B) ratio of Gilead Sciences, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Gilead Sciences, Inc. (GILD) is currently 7.75.

Question 9

What is the Price-to-Sales (P/S) ratio of GILD?

Accepted Answer

Based on trailing twelve-month data, Gilead Sciences, Inc. (GILD) trades at a Price-to-Sales (P/S) ratio of 5.95.

Question 10

What is Gilead Sciences, Inc.'s Return on Equity (ROE)?

Accepted Answer

Gilead Sciences, Inc. (GILD) has a Return on Equity (ROE) of 41.01%, representing its profitability relative to shareholder equity.